Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avenue, Biocryst, Estrella, Janssen, Novo Nordisk, Scisparc, Soligenix, Vertex.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abveris, Allergan, Alnylam, Endo, F-star, ICER, Icon, Invox, Leo Pharma, Les Laboratoires, Medicinova, Medison, Novelion, Olema, Orchard, Par, Qiagen, Sino, Sumitovant, Sumitoma, Twist Bioscience, Myovant.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Areteia, Astellas, Astrazeneca, Bergenbio, Bionomics, Clene, CNS, Eli Lilly, First Wave, Genfleet, Gensight, Lantern, Microbion, Ribon, Springworks, Vaccinex.

Biopharmas raising money in public or private financings, including: Allorion, Seelos, Tracon.

New hires and promotions in the biopharma industry, including: Alligator, Diamyd, Owkin.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Respiree.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alverno, Brain Scientific, Clarapath, Crosscope, Devyser, Durastat, Exact Sciences, Hansraj Nayyar, Ibex Medical, Intelligent Bio, Mindpeak, Paige AI, Qiagen, Servier, Titan, Vesteck, Viecure,

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allosource, Durin Technologies, Masimo, Proteomedix.